CORT ROA | CORCEPT THERAPEUTICS INC

CORCEPT THERAPEUTICS INC ROA

Return on assets (ROA) is the profit a company earns for every dollar of assets it uses, shown as a percentage. It is net income divided by total assets, and the table shows both amounts. Because assets are funded by lenders as well as shareholders, ROA is not inflated by borrowing the way ROE can be, and it is naturally lower for businesses that need many factories, stores or other assets. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

CORCEPT THERAPEUTICS INC roa for the quarter ending 2026-06-30 was 6.21%, a 62.75% decline year-over-year.
CORCEPT THERAPEUTICS INC roa for the quarter ending 2026-03-31 was 5.81%, a 63.30% decline year-over-year.
CORCEPT THERAPEUTICS INC roa for the quarter ending 2025-12-31 was 11.91%, a 29.10% decline year-over-year.
CORCEPT THERAPEUTICS INC roa for the quarter ending 2025-09-30 was 12.88%, a 28.75% decline year-over-year.
CORCEPT THERAPEUTICS INC roa for fiscal 2025 was 11.91%, a 29.10% decline from fiscal 2024.
CORCEPT THERAPEUTICS INC roa for fiscal 2024 was 16.80%, a 1.63% decline from fiscal 2023.
CORCEPT THERAPEUTICS INC roa for fiscal 2023 was 17.08%, a 1.76% decline from fiscal 2022.
CORCEPT THERAPEUTICS INC roa for fiscal 2022 was 17.38%, a 34.53% decline from fiscal 2021.

Available history: 2010-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical ROA

Date	ROA	Net income 12 month	Net income 3 month	Total assets
2026-06-30	6.21%	$55.18M	$42.99M	$888.7M
2026-03-31	5.81%	$47.34M	-$31.76M	$814.88M
2025-12-31	11.91%	$99.65M	$24.29M	$836.65M
2025-09-30	12.88%	$106.11M	$19.67M	$823.61M
2025-06-30	16.67%	$133.66M	$35.15M	$801.72M
2025-03-31	15.83%	$133.99M	$20.55M	$846.46M
2024-12-31	16.80%	$141.21M	$30.75M	$840.55M
2024-09-30	18.08%	$141.82M	$47.21M	$784.26M
2024-06-30	17.63%	$125.98M	$35.49M	$714.56M
2024-03-31	17.99%	$118.02M	$27.76M	$655.94M
2023-12-31	17.08%	$106.14M	$31.36M	$621.52M
2023-09-30	15.38%	$91.39M	$31.38M	$594.02M
2023-06-30	18.03%	$94.62M	$27.53M	$524.63M
2023-03-31	15.30%	$94.5M	$15.88M	$617.85M
2022-12-31	17.38%	$101.42M	$16.60M	$583.43M
2022-09-30	21.92%	$116.87M	$34.61M	$533.26M
2022-06-30	22.71%	$112.73M	$27.41M	$496.36M
2022-03-31	23.89%	$111.84M	$22.80M	$468.12M
2021-12-31	26.55%	$112.51M	$32.05M	$423.76M
2021-09-30	18.18%	$106.45M	$30.47M	$585.4M
2021-06-30	17.17%	$97.61M	$26.52M	$568.48M
2021-03-31	18.00%	$99.41M	$23.46M	$552.4M
2020-12-31	18.54%	$106.01M	$25.99M	$571.73M
2020-09-30	20.48%	$109.4M	$21.63M	$534.13M
2020-06-30	22.92%	$114.11M	$28.33M	$497.82M
2020-03-31	23.79%	$105.97M	$30.07M	$445.49M
2019-12-31	22.84%	$94.18M	$29.38M	$412.31M
2019-09-30	23.65%	$86.81M	$26.34M	$367.02M
2019-06-30	23.80%	$78.22M	$20.19M	$328.68M
2019-03-31	23.80%	$76.23M	$18.27M	$320.21M
2018-12-31	24.19%	$75.41M	$22.01M	$311.69M
2018-09-30	50.62%	$151.73M	$17.75M	$299.75M
2018-06-30	53.85%	$147.74M	$18.20M	$274.38M
2018-03-31	58.52%	$142.19M	$17.46M	$242.98M
2017-12-31	58.55%	$129.12M	$98.33M	$220.54M
2017-09-30	31.98%	$35.39M	$13.76M	$110.67M
2017-06-30	27.98%	$24.22M	$12.65M	$86.54M
2017-03-31	16.65%	$12.55M	$4.39M	$75.34M
2016-12-31	11.84%	$8.14M	$4.60M	$68.75M
2016-09-30	7.15%	$4.5M	$2.58M	$62.93M
2016-06-30	2.32%	$1.32M	$977.00K	$56.84M
2016-03-31	-3.02%	-$1.6M	-$19.00K	$52.91M
2015-12-31	-12.35%	-$6.41M	$959.00K	$51.9M
2015-09-30	-23.28%	-$11.26M	-$601.00K	$48.38M
2015-06-30	-34.47%	-$16.67M	-$1.94M	$48.36M
2015-03-31	-46.21%	-$22.28M	-$4.83M	$48.22M
2014-12-31	-90.62%	-$31.38M	-$3.90M	$34.63M
2014-09-30	-103.91%	-$38.61M	-$6.01M	$37.16M
2014-06-30	-98.02%	-$43.51M	-$7.55M	$44.39M
2014-03-31	-90.59%	-$47.86M	-$13.93M	$52.83M
2013-12-31	-72.94%	-$46.01M	-$11.12M	$63.08M
2013-09-30	-64.75%	-$46.01M	-$10.91M	$71.06M
2013-06-30	-54.46%	-$43.4M	-$11.90M	$79.69M
2013-03-31	-44.36%	-$39.1M	-$12.08M	$88.14M
2012-12-31	-38.37%	-$38.05M	-$11.12M	$99.17M
2012-09-30	-34.93%	-$36.86M	-$8.29M	$105.52M
2012-06-30	-90.64%	-$35M	-$7.60M	$38.62M
2012-03-31	-84.61%	-$36.29M	-$11.03M	$42.89M
2011-12-31	-81.22%	-$32.35M	-$9.94M	$39.83M
2011-09-30	-63.63%	-$29.51M	-$6.43M	$46.38M
2011-06-30	-57.25%	-$30.18M	-$8.88M	$52.72M

Annual ROA

Date	ROA	Net income 12 month	Total assets
2025-12-31	11.91%	$99.65M	$836.65M
2024-12-31	16.80%	$141.21M	$840.55M
2023-12-31	17.08%	$106.14M	$621.52M
2022-12-31	17.38%	$101.42M	$583.43M
2021-12-31	26.55%	$112.51M	$423.76M
2020-12-31	18.54%	$106.01M	$571.73M
2019-12-31	22.84%	$94.18M	$412.31M
2018-12-31	24.19%	$75.41M	$311.69M
2017-12-31	58.55%	$129.12M	$220.54M
2016-12-31	11.84%	$8.14M	$68.75M
2015-12-31	-12.35%	-$6.41M	$51.9M
2014-12-31	-90.62%	-$31.38M	$34.63M
2013-12-31	-72.94%	-$46.01M	$63.08M
2012-12-31	-38.37%	-$38.05M	$99.17M
2011-12-31	-81.22%	-$32.35M	$39.83M
2010-12-31	-103.43%	-$25.97M	$25.1M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
BridgeBio Pharma, Inc. (BBIO)	United States	$12.947B	-20.72
Summit Therapeutics Inc. (SMMT)	United States	$13.071B	-13.21
BIOMARIN PHARMACEUTICAL INC (BMRN)	United States	$11.879B	151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)	United States	$11.859B	-38.17
Elanco Animal Health Inc (ELAN)	United States	$11.177B	-61.80
Jazz Pharmaceuticals plc (JAZZ)		$15.333B	16.07
Axsome Therapeutics, Inc. (AXSM)	United States	$10.274B	-66.82
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)	United States	$9.331B	-42.28
CYTOKINETICS INC (CYTK)	United States	$9.130B	-11.86
Protagonist Therapeutics, Inc (PTGX)	United States	$8.883B	95.52